Renalsense Raises $14M Series A Funding To Bolster Global Commercialization And Expand Its Product Line
Renalsense Raises $14M Series A Funding To Bolster Global Commercialization And Expand Its Product Line
11/22/21, 9:00 AM
Location
jerusalemMoney raised
$14 million
Round Type
series a
RenalSenseTM, a leader in real-time renal diagnostics, today announced it has secured $14M to bolster the global commercialization of its current product, the Clarity RMS, expand clinical validation to additional clinical settings, and advance the release of its next generation products based on its sensor platform. The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.
Company Info
Location
jerusalem, jerusalem district, israel
Additional Info
RenalSense is a privately-owned medical device company dedicated to real-time renal diagnostics. The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.
SOURCE RenalSense